Relief from moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause
Divigel® eliminated nearly 90% of hot flashes in 12 weeks and reduced hot flashes by nearly HALF in as little as 2 weeks (1 mg/day).2
Divigel® is a cool, clear estradiol gel that’s easy to apply. It comes in small packets that are convenient for travel. Divigel® is applied once a day to a small area of the upper thigh. Divigel® is invisible and odorless when dry, and leaves no sticky residue.
To reduce the risk of transmission, advise patients to wash hands, avoid skin contact until gel is completely dried, and cover the application site.
The Divigel® Product Lineup
Available in five strengths including the lowest FDA-Approved dose of transdermal estradiol gel or spray: 0.25 mg, 0.5 mg, 0.75 mg, 1 mg and 1.25 mg estradiol to provide tailored relief of vasomotor symptoms to your patients.3
Unlock Patient Savings
Divigel® is one of the lowest cost transdermal estrogen gels.4 Save more money for your patients with the Divigel® Patient Savings Coupon.
Get Divigel® Samples
If you are a physician or other healthcare professional in the U.S., you can receive Divigel® samples by mail to support patient trial and use. Divigel® samples come with a convenient travel case for your patients.
If your practice is in a location where we have a sales representative, one will visit your office to provide you with Divigel® information and samples.
1. This information is an estimate derived from the use of information under license from the following IQVIA information service: NPA™, for the period 2019. IQVIA expressly reserves all rights, including rights of copying, distribution and republication.
2. Hedrick RE, Ackerman RT, Koltun WD, Halvorsen MB, Lambrecht LJ. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2009;16(1):132-140.
3. Orange Book: Approved Drug Products with Therapeutic equivalence Evaluations. U.S. Food & Drug Administration. Accessed February 13, 2020. https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm
4. Data on file, Osmotica Pharmaceuticals, November 2019.